CAS 105026-50-4
:morpholinoanthracycline MX2
Description:
Morpholinoanthracycline MX2, with the CAS number 105026-50-4, is a synthetic derivative of anthracycline, a class of compounds known for their potent antitumor properties. This compound features a morpholino group, which enhances its solubility and potentially alters its pharmacokinetic profile compared to traditional anthracyclines. Morpholinoanthracycline MX2 exhibits a mechanism of action that typically involves intercalation into DNA, leading to disruption of replication and transcription processes, ultimately inducing apoptosis in cancer cells. Its structural modifications aim to improve selectivity and reduce cardiotoxicity, a common side effect associated with conventional anthracyclines. The compound is primarily investigated for its efficacy against various malignancies, and ongoing research focuses on its therapeutic potential, optimal dosing regimens, and side effect profiles. As with many chemotherapeutic agents, understanding its pharmacodynamics and pharmacokinetics is crucial for maximizing its clinical benefits while minimizing adverse effects.
Formula:C30H35NO11
InChI:InChI=1S/C30H35NO11/c1-3-30(39)12-17(42-18-11-15(24(33)13(2)41-18)31-7-9-40-10-8-31)20-23(29(30)38)28(37)21-22(27(20)36)26(35)19-14(25(21)34)5-4-6-16(19)32/h4-6,13,15,17-18,24,29,32-33,36-39H,3,7-12H2,1-2H3
InChI key:InChIKey=OPBPMGYBSDKJBT-UHFFFAOYSA-N
SMILES:OC=1C2=C(C(OC3CC(C(O)C(C)O3)N4CCOCC4)CC(CC)(O)C2O)C(O)=C5C1C(=O)C=6C(C5=O)=C(O)C=CC6
Synonyms:- (7R,8R,10S)-8-Ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-10-[[2,3,6-trideoxy-3-(4-morpholinyl)-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione
- (7S-9R,10R)-3'-Deamino-3'-(4-morpholinyl)-13-deoxy-10-hydroxycarminomycin
- 3-Ethyl-3,4,5,10,12-Pentahydroxy-6,11-Dioxo-1,2,3,4,6,11-Hexahydrotetracen-1-Yl 2,3,6-Trideoxy-3-Morpholin-4-Ylhexopyranoside
- 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-8-ethyl-10-((3-(4-morpholinyl)-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-1,6,7,8,11-pentahydroxy-
- 5,12-Naphthacenedione, 8-ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-10-((2,3,6-trideoxy-3-(4-morpholinyl)-alpha-L-lyxo-hexopyranosyl)oxy)-
- 5,12-Naphthacenedione, 8-ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-10-[[2,3,6-trideoxy-3-(4-morpholinyl)-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl]oxy]-, (7R,8R,10S)-
- Antibiotic MX 2
- MX 2 (anthracycline)
- Morpholinyl oxaunomycin
- Mx 2
- [7S,9R,10R]-3′-Deamino-3′-(4-morpholinyl)-13-deoxo-10-hydroxycarminomycin
- 5,12-Naphthacenedione, 8-ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-10-[[2,3,6-trideoxy-3-(4-morpholinyl)-α-L-lyxo-hexopyranosyl]oxy]-, (7R,8R,10S)-
- Morpholinoanthracycline MX2
- See more synonyms
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 1 products.
Anthracycline
CAS:<p>Anthracycline is a class of chemotherapy drugs, which are anthraquinone antibiotics derived from the bacterial genus Streptomyces. They exert their therapeutic effects primarily through intercalation into DNA, disrupting the function of enzymes such as topoisomerase II, thus preventing the transcription and replication processes in rapidly dividing cancer cells. Furthermore, they generate free radicals, leading to oxidative stress and subsequent cell damage. These mechanisms collectively result in apoptosis of malignant cells. Anthracyclines are utilized extensively in oncology for the treatment of various malignancies, including leukemias, lymphomas, breast cancer, and sarcomas. The efficacy of anthracyclines in inhibiting tumor growth must be balanced against their cardiotoxic potential, which is a significant consideration in their clinical use. This dual nature makes them both pivotal and challenging in chemotherapy regimens, necessitating careful management and monitoring throughout treatment.</p>Formula:C30H35NO11Purity:Min. 95%Molecular weight:585.60 g/mol
